5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 2, 2015, Pages 146-153

  Hu, Xiao Yun ^a   Liang, Ji Yun ^a   Guo, Xue Jun ^a   Liu, Li ^a   Guo, Ya Bing ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; Apigenin; Apoptosis; Chemosensitivity; Hepatocellular carcinoma

Indexed keywords

APIGENIN; CASPASE 3; DIGOXIGENIN; FLUOROURACIL; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; ENZYME ACTIVATION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NICK END LABELING; NONHUMAN; PROPIDIUM IODIDE ASSAY; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG SCREENING; LIVER NEOPLASMS; METABOLISM; MITOCHONDRION; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APIGENIN; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL LINE, TUMOR; DRUG SYNERGISM; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, NUDE; MITOCHONDRIA; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920927046     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12333     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55: 74-108.
2. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 2008; 48(Suppl. 1): S20-37.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
4. European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer. Clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908-43.
5. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25: 259-62.
6. Qin S, Bai Y, Lim HY et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol. 2013; 31: 3501-8.
7. Alberts SR, Reid JM, Morlan BW et al. Gemcitabine and docetaxel for hepatocellular carcinoma: A Phase II North Central Cancer Treatment Group clinical trial. Am. J. Clin. Oncol. 2012; 35: 418-23.
8. Cao H, Phan H, Yang LX. Improved chemotherapy for hepatocellular carcinoma. Anticancer Res. 2012; 32: 1379-86.
9. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: How hopeful should we be? Oncologist 2006; 11: 790-800.
10. Lefort EC, Blay J. Apigenin and its impact on gastrointestinal cancers. Mol. Nutr. Food Res. 2013; 57: 126-44.
11. Choi EJ, Kim GH. Apigenin induces apoptosis through a mitochondria/caspase-pathway in human breast cancer MDA-MB-453 Cells. J. Clin. Biochem. Nutr. 2009; 44: 260-5.
12. Kim BR, Jeon YK, Nam MJ. A mechanism of apigenin-induced apoptosis is potentially related to anti-angiogenesis and anti-migration in human hepatocellular carcinoma cells. Food Chem. Toxicol. 2011; 49: 1626-32.
13. Masuelli L, Marzocchella L, Quaranta A et al. Apigenin induces apoptosis and impairs head and neck carcinomas EGFR/ErbB2 signaling. Front Biosci. 2011; 16: 1060-8.
14. Turktekin M, Konac E, Onen HI, Alp E, Yilmaz A, Menevse S. Evaluation of the effects of the flavonoid apigenin on apoptotic pathway gene expression on the colon cancer cell line (HT29). J. Med. Food 2011; 14: 1107-17.
15. Gupta S, Afaq F, Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem. Biophys. Res. Commun. 2001; 287: 914-20.
16. Chan LP, Chou TH, Ding HY et al. Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. Biochim. Biophys. Acta 2012; 1820: 1081-91.
17. Lee SH, Ryu JK, Lee KY et al. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 2008; 259: 39-49.
18. Boucher E, Corbinais S, Brissot P, Boudjema K, Raoul JL. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother. Pharmacol. 2002; 50: 305-8.
19. Budhraja A, Gao N, Zhang Z et al. Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol. Cancer Ther. 2012; 11: 132-42.
20. Chou TH, Ding HY, Hung WJ, Liang CH. Antioxidative characteristics and inhibition of alpha-melanocyte-stimulating hormone-stimulated melanogenesis of vanillin and vanillic acid from Origanum vulgare. Exp. Dermatol. 2010; 19: 742-50.
21. Johnson JL, Gonzalez de Mejia E. Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro. Food Chem. Toxicol. 2013; 60: 83-91.
22. Shukla S, Gupta S. Apigenin: A promising molecule for cancer prevention. Pharm. Res. 2010; 27: 962-78.
23. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat. 2004; 7: 97-110.
24. Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer. The roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid. Redox Signal. 2012; 16: 1295-322.
25. Andersen MR, Sweet E, Lowe KA, Standish LJ, Drescher CW, Goff BA. Dangerous combinations: Ingestible CAM supplement use during chemotherapy in patients with ovarian cancer. J. Altern. Complement. Med. 2013; 19: 714-20.
26. Sak K. Chemotherapy and dietary phytochemical agents. Chemother. Res. Pract. 2012; 2012: 282570.
27. Xu Y, Xin Y, Diao Y et al. Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells. PLoS ONE 2011; 6: e29169.
28. Zhang Y, Zhao L, Li X et al. V8, a newly synthetic flavonoid, induces apoptosis through ROS-mediated ER stress pathway in hepatocellular carcinoma. Arch. Toxicol. 2014; 88: 97-107.
29. Liu H, Jiang C, Xiong C, Ruan J. DEDC, a new flavonoid induces apoptosis via a ROS-dependent mechanism in human neuroblastoma SH-SY5Y cells. Toxicol In Vitro 2012; 26: 16-23.
30. Tamm C, Zhivotovsky B, Ceccatelli S. Caspase-2 activation in neural stem cells undergoing oxidative stress-induced apoptosis. Apoptosis 2008; 13: 354-63.
31. Skulachev VP. Bioenergetic aspects of apoptosis, necrosis and mitoptosis. Apoptosis 2006; 11: 473-85.
32. Kim IH, Kim SW, Kim SH et al. Parthenolide-induced apoptosis of hepatic stellate cells and anti-fibrotic effects in an in vivo rat model. Exp. Mol. Med. 2012; 44: 448-56.
33. Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention. Progress, potential and promise. Int. J. Oncol. 2007; 30: 233-45.
34. Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem. Pharmacol. 2008; 76: 1340-51.
35. Nguyen Ngoc TD, Son YO, Lim SS et al. Sodium fluoride induces apoptosis in mouse embryonic stem cells through ROS-dependent and caspase- and JNK-mediated pathways. Toxicol. Appl. Pharmacol. 2012; 259: 329-37.
36. Zhang H, Holzgreve W, De Geyter C. Bcl2-L-10, a novel anti-apoptotic member of the Bcl-2 family, blocks apoptosis in the mitochondria death pathway but not in the death receptor pathway. Hum. Mol. Genet. 2001; 10: 2329-39.